Literature DB >> 21821491

SEOM guidelines: non-seminomatous germ cell cancer (NSGCC).

Pablo Maroto1, Xavier Garcí Del Muro, Javier Sastre, Dolores Isla.   

Abstract

Non-seminomatous germ cell cancer (NSGCC) is a curable disease; its treatment has not essentially changed since the 1980s. BEP (bleomycin, etoposide, cisplatin) chemotherapy remains the standard of care. NSGCC's management can be summarised by three trees of decision, which contemplate staging, treatment with chemotherapy and management of postchemotherapy residual disease. The role of high-dose chemotherapy remains to be established. TIP (paclitaxel, iposfamide, cisplatin) chemotherapy is still the standard salvage treatment for patients progressing after BEP chemotherapy. Surgical removal of any residual disease is mandatory. For patients with poor prognosis, consultation with a centre of expertise is strongly recommended.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21821491     DOI： 10.1007/s12094-011-0698-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  9 in total

1.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Authors:  K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

Review 2.  Review of late complications of treatment and late relapse in testicular cancer.

Authors:  Eleni Efstathiou; Christopher J Logothetis
Journal:  J Natl Compr Canc Netw       Date:  2006-11       Impact factor: 11.908

3.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

Authors:  C R Nichols; P J Catalano; E D Crawford; N J Vogelzang; L H Einhorn; P J Loehrer
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

4.  Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.

Authors:  S B Saxman; D Finch; R Gonin; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

6.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

7.  Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours.

Authors:  P Maroto; X García del Muro; J Aparicio; L Paz-Ares; J A Arranz; J Guma; J Terrassa; J Barnadas; J Dorta; J R Germà-Lluch
Journal:  Ann Oncol       Date:  2005-08-26       Impact factor: 32.976

Review 8.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Authors:  H J Schmoll; R Souchon; S Krege; P Albers; J Beyer; C Kollmannsberger; S D Fossa; N E Skakkebaek; R de Wit; K Fizazi; J P Droz; G Pizzocaro; G Daugaard; P H M de Mulder; A Horwich; T Oliver; R Huddart; G Rosti; L Paz Ares; O Pont; J T Hartmann; N Aass; F Algaba; M Bamberg; I Bodrogi; C Bokemeyer; J Classen; S Clemm; S Culine; M de Wit; H G Derigs; K P Dieckmann; M Flasshove; X Garcia del Muro; A Gerl; J R Germa-Lluch; M Hartmann; A Heidenreich; W Hoeltl; J Joffe; W Jones; G Kaiser; O Klepp; S Kliesch; L Kisbenedek; K U Koehrmann; M Kuczyk; M P Laguna; O Leiva; V Loy; M D Mason; G M Mead; R P Mueller; N Nicolai; G O N Oosterhof; T Pottek; O Rick; H Schmidberger; F Sedlmayer; W Siegert; U Studer; S Tjulandin; H von der Maase; P Walz; S Weinknecht; L Weissbach; E Winter; C Wittekind
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

9.  Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

Authors:  Gordon J Rustin; Graham M Mead; Sally P Stenning; Paul A Vasey; Nina Aass; Robert A Huddart; Michael P Sokal; Jonathan K Joffe; Stephen J Harland; Sarah J Kirk
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544
  9 in total
  2 in total

1.  Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors.

Authors:  J Aparicio
Journal:  Clin Transl Oncol       Date:  2014-02-15       Impact factor: 3.405

2.  Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.

Authors:  Ignacio García-Escobar; Lucía Parrilla; Laura Montejano Ortega; Daniel Castellanos; María Ángeles Montalbán Pallarés; Hernán Cortés-Funés
Journal:  Mol Clin Oncol       Date:  2014-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.